Preferred Label : Prostate Cancer Pathway;
NCIt related terms : Prostate cancer;
Alternative definition : KEGG: The identification of key molecular alterations in prostate-cancer cells implicates
carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27),
and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells.
Glutathione S-transferases (GSTP1) are detoxifying enzymes that catalyze conjunction
of glutathione with harmful, electrophilic molecules, thereby protecting cells from
carcinogenic factors. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1,
undergo genomic damage mediated by such carcinogens. NKX3.1, PTEN, and p27 regulate
the growth and survival of prostate cells in the normal prostate. Inadequate levels
of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation
and decreased apoptosis. After therapeutic reduction in the levels of testosterone
and dihydrotestosterone, the emergence of androgen-independent prostate cancer has
been associated with mutations in the androgen receptor (AR) that permit receptor
activation by other ligands, increased expression of androgen receptors accompanying
AR amplification, and ligand-independent androgen-receptor activation.;
KEGG ID : hsa05215;
Origin ID : C91517;
UMLS CUI : C2984325;
- Automatic exact mappings (from CISMeF team)
- See also inter- (CISMeF)
- Semantic type(s)
- has_gene_product_element
- pathway_has_gene_element
https://www.has-sante.fr/jcms/p_3483677/fr/biopsies-ciblees-dans-le-diagnostic-du-cancer-de-la-prostate-rapport-d-evaluation
2023
France
health technology assessment
diagnosis
Prostate Cancer Pathway
Assay Target Antigen
Prostate Carcinoma
Biopsy of Prostate
prostatic neoplasms
malignant neoplasm prostate
prostate cancer
evaluation studies as topic
NCI CTEP SDC Prostate Cancer Sub-Category Terminology
prostate biopsy
biopsy
biopsy of prostate, nos
no diagnosis
Cancer Diagnosis
neoplasm, malignant
Prostate Cancer pT2c TNM Finding v6 and v7
---
https://pgtmsite.files.wordpress.com/2024/01/docetaxel_prostate_pgtm_20050407.pdf
2005
Canada
drug information
Docetaxel
prostatism, nos
Prostate Cancer Pathway
NCI CTEP SDC Prostate Cancer Sub-Category Terminology
Prostate Carcinoma
prostate cancer
docetaxel
docetaxel
neoplasm, malignant
Prostate Cancer pT2c TNM Finding v6 and v7
prostatic neoplasms
prostate, nos
Docetaxel
malignant neoplasm prostate
Refractory Carcinoma
---